Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
Channel Therapeutics (NYSE American: CHRO), a company focused on developing non-opioid pain treatment therapeutics, announced that its 2024 Annual Report filed on March 27, 2025, included an audit opinion with a going concern emphasis of matter paragraph from its independent registered public accounting firm. This disclosure is required by NYSE American LLC Company Guide Sections 410(h) and 610(b). The company clarified that this announcement does not represent any changes or amendments to their consolidated financial statements or their 2024 Annual Report.
Channel Therapeutics (NYSE American: CHRO), un'azienda specializzata nello sviluppo di terapie per il trattamento del dolore non oppioide, ha annunciato che il suo Rapporto Annuale 2024, depositato il 27 marzo 2025, include un parere di revisione con un paragrafo di enfasi sulla continuit脿 aziendale da parte della sua societ脿 di revisione contabile indipendente registrata. Questa comunicazione 猫 richiesta dalle sezioni 410(h) e 610(b) della Guida per le societ脿 di NYSE American LLC. L'azienda ha chiarito che questo annuncio non comporta modifiche o integrazioni ai loro bilanci consolidati o al Rapporto Annuale 2024.
Channel Therapeutics (NYSE American: CHRO), una empresa dedicada al desarrollo de tratamientos terap茅uticos para el dolor no opioides, anunci贸 que su Informe Anual 2024 presentado el 27 de marzo de 2025 incluye una opini贸n de auditor铆a con un p谩rrafo de 茅nfasis en la continuidad operativa emitido por su firma independiente de contadores p煤blicos registrados. Esta divulgaci贸n es requerida por las secciones 410(h) y 610(b) de la Gu铆a de Compa帽铆as de NYSE American LLC. La empresa aclar贸 que este anuncio no representa cambios o enmiendas a sus estados financieros consolidados ni a su Informe Anual 2024.
毂勲剱 韰岆澕頁嫳鞀�(NYSE American: CHRO)電� 牍勲鞎届劚 韱奠 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 須岇偓搿�, 2025雲� 3鞗� 27鞚� 鞝滌稖頃� 2024雲� 鞐半 氤搓碃靹滌棎 霃呺 瓿奠澑須岅硠氩曥澑鞚� 瓿勳啀旮办梾 臁挫啀鞐� 甏�頃� 臧曥“鞚橁铂 雼澖鞚� 韽暔霅橃棃鞚岇潉 氚滍憸頄堨姷雼堧嫟. 鞚� 瓿奠嫓電� NYSE American LLC 須岇偓 臧�鞚措摐 靹轨厴 410(h) 氚� 610(b)鞐� 霐半澕 鞖旉惮霅橂姅 靷暛鞛呺媹雼�. 須岇偓電� 鞚措矆 氚滍憸臧� 鞐瓣舶 鞛鞝滍憸雮� 2024雲� 鞐半 氤搓碃靹滌棎 雽�頃� 氤�瓴届澊雮� 靾橃爼 靷暛鞚� 鞚橂頃橃 鞎婋姅雼り碃 氇呿檿頌� 氚濏様鞀惦媹雼�.
Channel Therapeutics (NYSE American : CHRO), une soci茅t茅 sp茅cialis茅e dans le d茅veloppement de traitements th茅rapeutiques contre la douleur non opio茂des, a annonc茅 que son rapport annuel 2024, d茅pos茅 le 27 mars 2025, comportait une opinion d'audit incluant un paragraphe d'accentuation sur la continuit茅 d'exploitation 茅manant de son cabinet d'expertise comptable ind茅pendant enregistr茅. Cette divulgation est exig茅e par les sections 410(h) et 610(b) du guide des soci茅t茅s de NYSE American LLC. La soci茅t茅 a pr茅cis茅 que cette annonce ne constitue pas une modification ou un amendement de ses 茅tats financiers consolid茅s ni de son rapport annuel 2024.
Channel Therapeutics (NYSE American: CHRO), ein Unternehmen, das sich auf die Entwicklung von nicht-opioid-basierten Schmerztherapeutika spezialisiert hat, gab bekannt, dass sein am 27. M盲rz 2025 eingereichter Jahresbericht 2024 eine Pr眉fungsmeinung mit einem Hinweis zur Unternehmensfortf眉hrung von seiner unabh盲ngigen registrierten Wirtschaftspr眉fungsgesellschaft enth盲lt. Diese Offenlegung ist gem盲脽 den Abschnitten 410(h) und 610(b) des NYSE American LLC Unternehmenshandbuchs erforderlich. Das Unternehmen stellte klar, dass diese Bekanntmachung keine 脛nderungen oder Erg盲nzungen der konsolidierten Finanzberichte oder des Jahresberichts 2024 darstellt.
- None.
- Going concern warning from auditors indicates substantial doubt about the company's ability to continue operations
- Potential risk of NYSE American delisting if financial condition doesn't improve
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (鈥淐hannel鈥� or the 鈥淐ompany鈥�), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph.
Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company's consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.
About Channel
Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company鈥檚 initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit or follow us on聽social media.
Channel Media and Investor Inquires:
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
FAQ
What does the going concern warning mean for Channel Therapeutics (CHRO) stock?
Why did Channel Therapeutics (CHRO) receive a going concern warning in their 2024 annual report?
Could Channel Therapeutics (CHRO) be delisted from NYSE American due to the going concern warning?
What are the NYSE American listing requirements that Channel Therapeutics (CHRO) needs to comply with?
